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CLINICAL RESULTS OF INTERSTITIAL LASER COAGULATION 
FOR BENIGN PROSTATIC HYPERPLASIA USING DIODE LASER 
Sojun KINラ IsaoKANATANI and Teruo KONAMI 
From the Dψartment 01 Urologyフ OtsuMunicipal Hospital 
Interstitiallaser coagulation (ILCP) is currently considered to be one of the avenues for treatment 
ofbenign prostatic hyperplasia (BPH). The ef:五cacyand effectiveness of the treatmentぅ}問問verラhave
not been well clarified. Here we report the outcome oftreatment in benign prostatic hyperplasia using 
ILCP. Twenty patients with BPH who underwent interstitial laser coagulation using a diode laser 
between March and December 1998 were investigated. Our results showed that there are significant 
improvements in prostate symptom score and quality of life index after the treatment. According to 
the e伍cacycri teriaラ 70%of the patients showed clinical improvement of both scores at 1 monthう and
more than 90% of the patients at 3 months. The reduction of prostate volume was observed after 1 
month of treatment and continued for 6 months. The improvement on peak fiow rate was observed in 
50% of the patients at 3 months and in 73.3% of the patients at 6 months. The overall efficacy rates 
were 62.5%う85.0%and 100% ofthe patients at 1ラ3and 6 monthsぅrespectively. In al 20 patients the 
complications were minimal. No blood transfusion was required in any patients. Howeverラ one
patient experienced both epididymitis and prostatic abscess and was treated with conservative therapy. 
In conclusionラ interstitiallaser coagulation using a diode laser is a very effective means for the 
treatment ofbenign prostatic hyperplasia. Because ofits less invasive natureうwestrongly recommend 
that ILCP be the major way of treatment for benign prostatic hyperplasia. 
(Acta Urol. Jpn. 45: 749-753う 1999)
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52-95 (平均 68.6土10.3) 歳で術前の I-PSSは










750 泌尿紀要 45巻 1号 1999年
Table 1 Criteria for treatment efficacy in BPH 
1. Symptom* 2. QOL* 3. Function* 4. Anatomy 
Efficacy 
post/pre (I-PSS) pre-post (QOL index) post-pre (Qmax) post/Vproe i (ProsI:ate ¥1olume) 
Excellent 孟0.25 孟4 孟10 ml/s 三五0.5
Good 三五0.5 3 孟 5 ml/s 三五0.75
Fair 三五0.75 2， 1 与さ 2.5 ml/s 孟0.9
Poor/Worse >0.75 三五O < 2.5 ml/s >0.9 
* Overall efficacy is the median of efficacy grades of 3 items : symptomぅQOLand function. 
Table 2. Sequential changes in clinical and voiding parameters 
lnitial 1 month 3 months 6 months 
I開PSS(0-35) 
Mean土SD 19.0土 4.8 12.2:1: 8.5 6.8:1: 4.1 7.9土 4.1
No. pts 20 17 20 15 
QOL index (0-6) 
Mean土SD 5.1土1.1 3.0土 2.0 1.8土1.6 1.9土1.6
No. pts 20 17 20 15 
Qmax (ml/sec) 
Mean土SD 7.6:1: 2.5 9.8:1: 3.6 10.6土 3.6 12.1土 3.0
No. pts 20 19 20 15 
Prostate volume (ml) 
Mean土SD 44.5土30.0 41.1土27.2 34.8土26.9 28.6土16.7
No. pts 20 19 20 15 
Postvoid residual volume (mI) 
Mean土SD 50.2土48.3 36.1土35.6 23.1土28.1 25.7土22.7




の深さ(先端から 18mm)まで刺入し， tissue adap-
tive modeにて設定温度 850Cで 1穿刺につき 3分間
レーザー照射を行った。照射回数は原則として前立線


















QOL index も1カ月後に 70.6%，3カ月後は
95.0%， 6カ月後は93.3%の有効率であり，自覚症状






(Fig. 2). 残尿量については 3カ月まで減少傾向が見
られたが以降は横這いであった.
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Fig. 1. Changes of e伍cacygrades in I-PSS and QOL index. Efficacy 
rate is more than 90% at 3 months postoperatively. 
考察
ILCPは1992年に Muschterら2)が報告して以来，
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Fig. 2. Changes of ef五cacygrades in peak fiow rate and prostate 
volume. 
Table 3. Overall efficacy 
1M 3M 6M 
No. pts 
n=16 n=20 n=15 
Excellent O 0.0% 5 25.0% 3 20.0% 
Good 5 31.3% 9 45.0% 8 53.3% 
Fair 5 31.3% 3 15.0% 4 26.7% 
Poor/Worse 6 37.5% 3 15.0% O 0.0% 
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Fig. 3. Postoperative medication. Mediation 
was stopped within 6 months postoper-























2) 他覚所見は前立腺体積は 1カ月後から減少し 6
カ月後まで減少傾向を示した. Qmaxも3カ月後に
半数が改善し6カ月後まで改善傾向を示した.
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